# A randomised double blind placebo controlled trial of the addition of metformin to optimal treatment in patients with chronic heart failure. Assessment by regional haemodynamics neurohumoral activation and symptomatic well being

Submission date	Recruitment status	Prospectively registered
12/09/2003	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
12/09/2003	Completed	Results
Last Edited	Condition category	[] Individual participant data
27/10/2015	Circulatory System	<ul><li>Record updated in last year</li></ul>

**Plain English summary of protocol**Not provided at time of registration

# Contact information

Type(s)

Scientific

Contact name

Dr AJ Cowley

#### Contact details

Department of Cardiovascular Medicine D Floor South Block Nottingham United Kingdom NG7 2UH

# Additional identifiers

EudraCT/CTIS number

IRAS number

#### ClinicalTrials.gov number

## Secondary identifying numbers

N0192080686

# Study information

#### Scientific Title

A randomised double blind placebo controlled trial of the addition of metformin to optimal treatment in patients with chronic heart failure. Assessment by regional haemodynamics neurohumoral activation and symptomatic well being

#### **Study objectives**

To determine whether metformin is of benefit in the treatment of patients with congestive heart failure.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Not provided at time of registration

#### Study design

Randomised controlled trial

## Primary study design

Interventional

# Secondary study design

Randomised controlled trial

# Study setting(s)

Not specified

## Study type(s)

Treatment

#### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Cardiovascular: Congestive heart failure (CHF)

#### **Interventions**

Randomised controlled trial.

#### Intervention Type

Drug

#### **Phase**

Not Applicable

# Drug/device/biological/vaccine name(s)

Metformin

#### Primary outcome measure

- 1. Regional haemodynamics
- 2. Neurohumoral
- 3. Symptomatic well being

# Secondary outcome measures

Not provided at time of registration

#### Overall study start date

15/02/2000

# Completion date

31/08/2004

# **Eligibility**

# Key inclusion criteria

Total number of subjects = 20

# Participant type(s)

**Patient** 

# Age group

**Not Specified** 

#### Sex

**Not Specified** 

# Target number of participants

20

#### Key exclusion criteria

Does not match inclusion criteria

#### Date of first enrolment

15/02/2000

#### Date of final enrolment

31/08/2004

# Locations

Countries of recruitment

#### England

**United Kingdom** 

Study participating centre
Nottingham University Hospitals NHS Trust
Nottingham
United Kingdom
NG7 2UH

# Sponsor information

#### Organisation

Department of Health (UK)

# Sponsor details

Richmond House 79 Whitehall London United Kingdom SW1A 2NL

# Sponsor type

Government

#### Website

http://www.doh.gov.uk

# Funder(s)

## Funder type

Hospital/treatment centre

#### **Funder Name**

Nottingham University Hospitals NHS Trust (UK)

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

Intention to publish date
Individual participant data (IPD) sharing plan

**IPD sharing plan summary**Not provided at time of registration